High-Grade Purification of Third-Generation HIV-Based Lentiviral Vectors by Anion Exchange Chromatography for Experimental Gene and Stem Cell Therapy Applications

  • Hazal Banu Olgun
  • Hale M. Tasyurek
  • Ahter D. Sanlioglu
  • Salih SanliogluEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 1879)


Lentiviral vectors (LVs) have been increasingly used in clinical gene therapy applications particularly due to their efficient gene transfer ability, lack of interference from preexisting viral immunity, and long-term gene expression they provide. Purity of LVs is essential in in vivo applications, for a high therapeutic benefit with minimum toxicity. Accordingly, laboratory scale production of LVs frequently involves transient cotransfection of 293T cells with packaging and transfer plasmids in the presence of CaPO4. After clearance of the cellular debris by low-speed centrifugation and filtration, lentivectors are usually concentrated by high-speed ultracentrifugation in sucrose cushion. Concentrated viral samples are then purified by anion exchange chromatography (AEX) after benzonase treatment to remove the residual cellular DNA. Here, we describe an improved practical method for LV purification using AEX, useful for experimental studies concerning gene and stem cell therapy.


Anion exchange chromatography Gene and cell therapy Lentivirus 



This study is supported by grants from Akdeniz University Scientific Research Administration Division (TYL-2015-1027) and the Scientific and Technological Research Council of Turkey (TUBITAK-112S114).


  1. 1.
    Ponder KP (2001) Vectors of gene therapy. In: Kresina TF (ed) An introduction to molecular medicine and gene therapy. Wiley-Liss, Inc., New York, pp 77–112Google Scholar
  2. 2.
    Lundstrom K, Boulikas T (2003) Viral and non-viral vectors in gene therapy: technology development and clinical trials. Technol Cancer Res Treat 2(5):471–486CrossRefGoogle Scholar
  3. 3.
    Glover DJ et al (2005) Towards safe, non-viral therapeutic gene expression in humans. Nat Rev Genet 6(4):299–310CrossRefGoogle Scholar
  4. 4.
    Hanna E et al (2017) Gene therapies development: slow progress and promising prospect. J Mark Access Health Policy 5(1):1265293CrossRefGoogle Scholar
  5. 5.
    Tasyurek HM, Eksi YE, Sanlioglu AD, Altunbas HA, Balci MK, Griffith TS, Sanlioglu S (2018) HIV-based lentivirus-mediated vasoactive intestinal peptide gene delivery protects against DIO animal model of Type 2 diabetes. Gene Ther Scholar
  6. 6.
    Tasyurek HM et al (2018) Therapeutic potential of lentivirus-mediated glucagon-like peptide-1 (GLP-1) gene therapy for diabetes. Hum Gene Ther. Scholar
  7. 7.
    Segura MM et al (2006) Downstream processing of oncoretroviral and lentiviral gene therapy vectors. Biotechnol Adv 24(3):321–337CrossRefGoogle Scholar
  8. 8.
    Segura MM, Kamen AA, Garnier A (2011) Overview of current scalable methods for purification of viral vectors. In: OW Merten A-RM (ed) Viral vectors for gene therapy. Humana Press, Totowa, NJ, pp 89–116CrossRefGoogle Scholar
  9. 9.
    Segura MM et al (2005) A novel purification strategy for retrovirus gene therapy vectors using heparin affinity chromatography. Biotechnol Bioeng 90(4):391–404CrossRefGoogle Scholar
  10. 10.
    Gandara C et al (2018) Manufacture of third-generation lentivirus for preclinical use, with process development considerations for translation to good manufacturing practice. Hum Gene Ther Methods 29(1):1–15CrossRefGoogle Scholar
  11. 11.
    Merten OW et al (2011) Large-scale manufacture and characterization of a lentiviral vector produced for clinical ex vivo gene therapy application. Hum Gene Ther 22(3):343–356CrossRefGoogle Scholar
  12. 12.
    Slepushkin V, Chang N, Cohen R (2003) Large-scale purification of a lentiviral vector by size exclusion chromatography or mustang Q ion exchange capsule. Bioprocess J 2:89–95CrossRefGoogle Scholar
  13. 13.
    Geraerts M et al (2005) Upscaling of lentiviral vector production by tangential flow filtration. J Gene Med 7(10):1299–1310CrossRefGoogle Scholar
  14. 14.
    Cooper AR et al (2011) Highly efficient large-scale lentiviral vector concentration by tandem tangential flow filtration. J Virol Methods 177(1):1–9CrossRefGoogle Scholar
  15. 15.
    Roush DJ, Lu Y (2008) Advances in primary recovery: centrifugation and membrane technology. Biotechnol Prog 24(3):488–495CrossRefGoogle Scholar
  16. 16.
    Burns JC et al (1993) Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci U S A 90(17):8033–8037CrossRefGoogle Scholar
  17. 17.
    Kutner RH et al (2009) Simplified production and concentration of HIV-1-based lentiviral vectors using HYPERFlask vessels and anion exchange membrane chromatography. BMC Biotechnol 9:10CrossRefGoogle Scholar
  18. 18.
    Transfiguracion J et al (2003) Size-exclusion chromatography purification of high-titer vesicular stomatitis virus G glycoprotein-pseudotyped retrovectors for cell and gene therapy applications. Hum Gene Ther 14(12):1139–1153CrossRefGoogle Scholar
  19. 19.
    Sastry L et al (2004) Evaluation of plasmid DNA removal from lentiviral vectors by benzonase treatment. Hum Gene Ther 15(2):221–226CrossRefGoogle Scholar
  20. 20.
    Ausubel LJ et al (2012) Production of CGMP-grade lentiviral vectors. Bioprocess Int 10(2):32–43PubMedPubMedCentralGoogle Scholar
  21. 21.
    Yu JH, Schaffer DV (2006) Selection of novel vesicular stomatitis virus glycoprotein variants from a peptide insertion library for enhanced purification of retroviral and lentiviral vectors. J Virol 80(7):3285–3292CrossRefGoogle Scholar
  22. 22.
    Rodrigues T et al (2006) Screening anion-exchange chromatographic matrices for isolation of onco-retroviral vectors. J Chromatogr B Analyt Technol Biomed Life Sci 837(1–2):59–68CrossRefGoogle Scholar
  23. 23.
    Merten OW et al (2014) Manufacturing of viral vectors: Part II. Downstream processing and safety aspects. Pharm Bioprocess 2(3):237–251CrossRefGoogle Scholar
  24. 24.
    Yamada K et al (2003) Lentivirus vector purification using anion exchange HPLC leads to improved gene transfer. Biotechniques 34(5):1074–1078, 1080CrossRefGoogle Scholar
  25. 25.
    Scherr M et al (2002) Efficient gene transfer into the CNS by lentiviral vectors purified by anion exchange chromatography. Gene Ther 9(24):1708–1714CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2018

Authors and Affiliations

  • Hazal Banu Olgun
    • 1
  • Hale M. Tasyurek
    • 1
  • Ahter D. Sanlioglu
    • 1
  • Salih Sanlioglu
    • 1
    Email author
  1. 1.Human Gene and Cell Therapy Center of Akdeniz University Hospitals and ClinicsAntalyaTurkey

Personalised recommendations